A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
for Focal Segmental Glomerulosclerosis
Drug: Brivekimig
16 locations incl. Birmingham
Sponsor: Sanofi
Sex: All·Age: 16 - 75
Code: NCT06500702·Phase 2·Recruiting